367 related articles for article (PubMed ID: 16698332)
1. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
[TBL] [Abstract][Full Text] [Related]
2. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
Greenberg B; Zannad F; Pitt B
Am J Cardiol; 2006 May; 97(10A):34F-40F. PubMed ID: 16698333
[TBL] [Abstract][Full Text] [Related]
3. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
Weir R; McMurray JJ
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
[TBL] [Abstract][Full Text] [Related]
4. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
5. An approach to heart failure and diabetes mellitus.
Fonarow GC
Am J Cardiol; 2005 Aug; 96(4A):47E-52E. PubMed ID: 16098844
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
7. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
8. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
Krantz MJ; Ambardekar AV; Kaltenbach L; Hernandez AF; Heidenreich PA; Fonarow GC;
Am J Cardiol; 2011 Jun; 107(12):1818-23. PubMed ID: 21482418
[TBL] [Abstract][Full Text] [Related]
9. Managing the patient with diabetes mellitus and heart failure: issues and considerations.
Fonarow GC
Am J Med; 2004 Mar; 116 Suppl 5A():76S-88S. PubMed ID: 15019865
[TBL] [Abstract][Full Text] [Related]
10. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
Milicić D
Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
[TBL] [Abstract][Full Text] [Related]
11. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Shah NC; Pringle S; Struthers A
J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients.
Struthers AD
Heart; 2006 Dec; 92(12):1728-31. PubMed ID: 16339814
[TBL] [Abstract][Full Text] [Related]
16. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
17. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
[TBL] [Abstract][Full Text] [Related]
18. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
Belenkov IuN; Mareev VIu; Skvortsov AA
Ter Arkh; 2008; 80(9):5-12. PubMed ID: 19555028
[No Abstract] [Full Text] [Related]
19. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
20. [Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning].
Sinagra G; Sabbadini G; Zecchin M; Di Lenarda A
G Ital Cardiol (Rome); 2007 Sep; 8(9):559-67. PubMed ID: 17972425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
